Sintetica SA recently celebrated its one hundredth anniversary with events that projected the company into the future.
During the morning of November 12, Sintetica, together with partners Fondazione AGIRE and Università della Svizzera Italiana, presented the first-ever Sintetica Innovation Award to a winning startup in a competition that was created to recognize promising and innovative Swiss start-ups in the fields of healthcare and life sciences. The finalist teams included:
InkVivo: A new 3D-printed implantable drug delivery patch used to deliver locally-acting analgesics and anti-inflammatory drugs during surgery, reducing systemic side effects of post-operative pain management and accelerating the recovery of the patient.
Hemotune: A novel blood purification technology that uses magnetic nano-beads covered with specific compounds to remove immunomodulators from the blood of patients suffering from life-threatening septic shock.
AnastoSeal by Veltist: An innovative sealing technology for use in abdominal surgery, specifically developed for reducing the incidence of post-surgical digestive leaks and prevent the occurrence of sepsis.
The winning submission, InkVivo, was presented the CHF 25,000 award, and all finalists received access to coaching resources provided by Università della Svizzera Italiana’s Startup Center.
The evening celebrations, were attended by important representatives from the worlds of science, academics, and public institutions, including Christian Vitta, State Councilor and Director of the Canton's Department of Finance and Economy and Raffaele De Rosa, Director of the Department of Health and Social Affairs and State Councilor. A scientific symposium titled "The Molecules of Life" included keynote speakers Prof. Filippo Mancia, Co-director of the Department of Physiology and Cellular Biophysics at Columbia University and Prof. Dr. med. Alain Borgeat, Director of the Department of Anesthesiology at Balgrist Orthopedic University Hospital in Zurich.
At the celebration, Sintetica unveiled an updated mission statement, reaffirming its commitment to improving therapies based on clinicians’ insights to improve patients’ lives. With leading products in anesthesia, analgesia, cardiovascular agents and muscle relaxants used in operative and emergency care in hospitals around the world, Sintetica focuses on reformulation of proven therapies for new administration modes, such as regional use for ambulatory surgery, intrathecal therapy or ready-to-use applications. Strong and trusting relationships with clinicians form the basis for the company’s quest to push the limits of science and technology to make therapies safer, easier to use, and better for patients.
A new visual identity, was unveiled as part of the celebrations, expressing the company’s commitment visually in form of a refreshed logo and corporate design that reflect its strong historical roots and projects Sintetica into the future. The new look and feel will be implemented gradually across all touchpoints in a phased approach.
“It was exciting and a real honor be joined by the winners and finalists of our first-ever Innovation Award, and to welcome distinguished guests to our Century Celebration,” said Dr. Miro Venturi, CEO of Sintetica SA. “With our refreshed visual identity, we celebrate our history, expand our horizons and prepare Sintetica for another century of improving patients’ lives.”